aftd-white-logo

Externally Led Patient-Focused Drug Development Meeting

A group of diverse persons participate in a virtual meeting

AFTD is proud to announce the release of Frontotemporal Degeneration: A Voice of the Patient Report. This landmark report summarizes and analyzes data and perspectives from more than 1,750 people living with FTD, care partners, caregivers, and family members. Participants shared vital insight through our March 5, 2021 Externally-Led Patient Focused Drug Development Meeting, as well as an FTD Insights Survey conducted with the FTD Disorders Registry. Channeling the resolve of a community, we offer this report to provide the FDA with data and insights to evaluate future studies and treatments for FTD, including behavioral variant FTD, FTD-ALS, primary progressive aphasia, corticobasal syndrome or degeneration, and progressive supranuclear palsy.

Watch the Meeting

Frontotemporal Degeneration: A Voice of the Patient Report

On October 27, 2021, reflecting input from more than 1,750 people, AFTD released our Voice of the Patient Report on FTD. We dedicate this report to all who have lost a loved one to FTD and to all who work to address this disease. We share your hope for a world with compassionate care, effective support, and a future free of FTD.

EL-PFDD Meeting Agenda (Held on March 5th, 2021)

Video Timestamp

Agenda

0:00:00 Opening Remarks
Susan L-J Dickinson, MSGC, CEO, The Association for Frontotemporal Degeneration (AFTD)
0:06:44 FDA Welcome Remarks
Michelle Campbell, PhD, Sr. Clinical Analyst for Stakeholder Engagement & Clinical Outcomes, Division of Neurology Products, FDA
0:11:14 Background on FTD
Brad Dickerson, MD, Director, Frontotemporal Disorders Unit, Massachusetts General Hospital, Professor of Neurology, Harvard Medical School
0:26:21 Introduction & Meeting Overview
James Valentine, JD, MHS, Meeting Moderator
0:33:41 Demographic Polling
0:51:05 Topic 1 Panel 1: Health Effects and Daily Impacts
1:18:38 Moderated audience discussion and polling
James Valentine, JD, MHS, Susan Dickinson, MSGC
2:34:45 Topic 2: Current & Future Approaches to Treatment
James Valentine, JD, MHS
2:36:15 Panel 2A: Perspectives on Sporadic FTD
3:06:26 Panel 2B: Perspectives on Genetic FTD
3:29:22 Moderated audience discussion and polling
James Valentine, JD, MHS, Susan L-J Dickinson, MSGC
4:51:30 Meeting Summary
Larry Bauer, RN, MA, Hyman, Phelps, & McNamara, P.C.
5:06:13 Next Steps & Closing Remarks
Susan L-J Dickinson, MSGC

Thank You to Our Sponsors

PLATINUM

Ionis_Logo

GOLD

LillyLogo
TauConsortium logo
Alector Logo
RCF-logo-600x232

SILVER

Acadia_Logo
Primary-Logo_CMYK-600x242
Bluefield_Logo
PassageBio_Logo
Wave_Logo
ALZ-Logo-Stacked
UCB_logo
cure PSP
Prevail-Therapeutics-logo
Biogen_Logo

BRONZE

Abbvie_Logo
denali therapeutics logo
aftd-white-logo
ftdregistry-logo-white

FTD DISORDERS REGISTRY

For AFTD research and industry collaboration, please contact Shana Dodge, PhD at [email protected]. For collaboration with FTD Disorders Registry, contact Dianna Wheaton, PhD at [email protected]. For press inquiries, email Matt Ozga at [email protected]. To learn more about sponsorship opportunities, email Liz Graham at [email protected]

The Association for Frontotemporal Degeneration
2700 Horizon Drive, Suite 120
King of Prussia, PA 19406

Call 1-866-507-7222 | Email [email protected] | Visit theaftd.org

© 2021 The Association for Frontotemporal Degeneration
All Rights Reserved

Have Questions?

Contact AFTD's HelpLine at

1-866-507-7222

or email [email protected]